Ra, Merck Partner to Develop Peptide Drugs in $200M Deal
By Catherine Shaffer
Wednesday, April 3, 2013
A new collaboration between Ra Pharmaceuticals Inc. and Merck & Co. Inc. will focus on harnessing the therapeutic power of peptide drugs through a platform technology that offers candidates pre-designed for cell permeability and oral bioavailability.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.